Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Silk Road Medical's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €135.5 Mil. Silk Road Medical's Total Assets for the quarter that ended in Mar. 2024 was €232.1 Mil.
Therefore, Silk Road Medical's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.58.
The historical rank and industry rank for Silk Road Medical's Equity-to-Asset or its related term are showing as below:
FRA:2OW'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.09 Med: 0.57 Max: 0.68
Current: 0.58
During the past 7 years, the highest Equity to Asset Ratio of Silk Road Medical was 0.68. The lowest was -4.09. And the median was 0.57.
FRA:2OW's Equity-to-Asset is ranked worse than 58.03% of 872
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs FRA:2OW: 0.58
Silk Road Medical Equity-to-Asset Historical Data
The historical data trend for Silk Road Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Silk Road Medical's Equity-to-Asset
For the Medical Devices subindustry, Silk Road Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Equity-to-Asset falls into.
Silk Road Medical Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Silk Road Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical (FRA:2OW) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Silk Road Medical Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:2OW has been successfully added to your 